During the International Headache Congress in Seoul from September 14 to 17, Chordate Medical is introducing the new brand Ozilia™ Migraine for the company’s migraine treatment. Ozilia™ Migraine replaces K.O.S as the brand name in all markets where Chordate is active.
“This is the next step in the rollout and commercialization of the treatment in our focus markets. Migraine is predominantly a women’s health matter, and the previous designation, K.O.S, has long felt as too technical and rather uninspiring as a brand. The meaning of the name Ozilia™ revolves around her need for freedom – and that is also the core of what we want to offer to all people in the world who suffer from migraines”, says Anders Weilandt, CEO of Chordate.
Ozilia™ Migraine will be showcased for the first time at the IHC in Seoul, the largest international platform for headache experts and migraine specialists.
“The interest in our study and its results is significant within the migraine field. Exhibiting at this congress is an excellent opportunity for us to introduce Ozilia™ Migraine as a drug-free treatment option with a very favorable side effect profile and long-lasting preventive effects.”